

**Table 1.** Baseline characteristics of patients with biopsy-proven NAFLD in the derivation cohort grouped by the severity of fibrosis (fibrosis stage F < 1 and fibrosis stage F ≥ 1)

	Fibrosis stage F < 1 (n = 19)	Fibrosis stage F ≥ 1 (n = 81)	<i>p</i>
Age (years)	42.84 ± 12.62	39.72 ± 12.68	0.335
Sex (men)	12 (63.16%)	57 (70.37%)	0.541
BMI (kg/m <sup>2</sup> )	25.25 ± 2.16	28.29 ± 5.35	0.021
Waist circumference (cm)	87.50 ± 6.13	96.64 ± 12.49	0.004
AST (U/l)	32.61 ± 14.48	52.93 ± 35.02	0.018
ALT (U/l)	51.67 ± 31.72	79.86 ± 56.53	0.045
TC (mmol/l)	5.21 ± 1.43	5.14 ± 1.30	0.904
TG (mmol/l)	2.37 ± 1.07	2.76 ± 1.65	0.349
HDL-C (mmol/l)	1.05 ± 0.24	0.97 ± 0.19	0.149
LDL-C (mmol/l)	3.30 ± 1.03	2.98 ± 0.96	0.218
HbA1c (%)	6.18 ± 1.46	6.45 ± 1.41	0.485
Creatinine (mmol/l)	70.72 ± 19.14	69.56 ± 14.41	0.775
eGFR	110.71 ± 22.19	114.89 ± 17.60	0.397
Hypertension (%)	4 (21.05%)	16 (19.75%)	0.899
T2DM (%)	5 (26.32%)	28 (34.57%)	0.491
Obesity (%)	7 (36.84%)	56 (69.14%)	0.009
Steatosis			
1	10 (52.63%)	27 (33.33%)	0.176
2	6 (31.58%)	25 (30.86%)	
3	3 (15.79%)	29 (35.80%)	
Ballooning			0.982
0	3 (15.79%)	14 (17.28%)	
1	11 (57.89%)	47 (58.02%)	
2	5 (26.32%)	20 (24.69%)	
Lobular inflammation			0.002
0	2 (10.53%)	0 (0.00%)	
1	16 (84.21%)	49 (60.49%)	
2	1 (5.26%)	31 (38.27%)	
3	0 (0.00%)	1 (1.23%)	

*Abbreviations:* ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; eGFR, estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; T2DM, type 2 diabetes; TG: triglyceride; TC: total cholesterol.